NEW YORK (GenomeWeb News) – RedPath Integrated Pathology today announced the execution of an agreement with preferred provider organization MultiPlan for RedPath's PathFinder TG test for pancreatic cancer.

The contract is the seventh inked by the Pittsburgh-based molecular diagnostics firm with a national PPO and expands the number of covered lives for the test to more than 74 million people, RedPath said. PathFinder TG produces mutational profiles to help physicians "resolve complex diagnostic dilemmas in patients who are at risk of cancer."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.